When two of the biggest names in GLP-1 therapy get put in the same trial, head to head, the results tend to settle arguments that have been running in comment sections for years. SURMOUNT-5, a Phase 3b trial comparing tirzepatide (Zepbound) directly against semaglutide (Wegovy) over 72 weeks, did exactly that — and the numbers weren’t particularly close.
The Head-to-Head Numbers
Published in the New England Journal of Medicine, SURMOUNT-5 found that tirzepatide produced a mean weight loss of 20.2%, compared to 13.7% with semaglutide, over the same 72-week window, in the same trial, under the same conditions. That’s not a marginal difference — it’s a gap of more than six percentage points between two drugs that are both, in isolation, considered highly effective by any historical standard for obesity pharmacotherapy. For a patient starting near 250 pounds, that difference works out to roughly 15 to 20 additional pounds lost with tirzepatide over semaglutide alone.
Why the Gap Exists
The mechanistic explanation is straightforward: semaglutide is a GLP-1 receptor monoagonist, activating a single hormone pathway. Tirzepatide is a dual agonist, activating both the GLP-1 and GIP receptors simultaneously. That second receptor appears to meaningfully amplify the metabolic effect rather than simply adding a small increment — which is also the underlying logic behind Eli Lilly’s newer, even more aggressive triple-agonist candidate, retatrutide, which adds a third receptor (glucagon) on top of GLP-1 and GIP.
What This Means in Practice
Head-to-head data like this matters more than dueling separate trials, because it removes a lot of the noise that makes cross-trial comparisons unreliable — different populations, different protocols, different eras of the drug class. SURMOUNT-5 is about as close to an apples-to-apples comparison as this category gets, and it’s a meaningful data point for anyone (patients or prescribers) weighing which drug to start with when both are genuinely available options. It doesn’t mean semaglutide is a weak choice — 13.7% average weight loss remains a strong clinical result by any pre-2021 standard — but it does mean tirzepatide currently holds a real, trial-confirmed efficacy edge over standard-dose semaglutide specifically.
Frequently Asked Questions
Does this mean everyone should switch to tirzepatide?
Not necessarily. Efficacy is one factor among several — cost, insurance coverage, side-effect tolerance, and individual response all vary. SURMOUNT-5 shows an average population-level difference, not a guarantee for any individual patient.
How does this compare to retatrutide?
Retatrutide’s early trial data has posted even larger average weight-loss numbers than tirzepatide, consistent with the pattern that adding receptor targets (GIP, then glucagon) tends to increase efficacy. It remains investigational as of this writing.
Were side effects also compared head-to-head?
Yes — SURMOUNT-5 tracked safety and tolerability alongside efficacy, with both drugs showing the class-typical gastrointestinal side effect profile, though rates and severity can differ by drug and dose.
This article is for educational purposes only and summarizes publicly available clinical trial data. It is not medical advice. Talk to your healthcare provider about which GLP-1 therapy is appropriate for you.